Oncimmune Expands Application Of Liquid Biopsy Auto-Antibody Technology
The company’s liquid biopsy test business is complemented by a patient-stratification service for pharmaceutical companies.
You may also be interested in...
Device financing totaled $1.6bn for the first quarter of 2019. Late-stage venture rounds were the most active category, led by Nuvaira's $79m Series E financing. Merger and acquisition activity reached $7.3bn; in the largest transaction of the quarter, Ethicon acquired Auris Health for up to $6bn. Diagnostics/research financing reached $1.7bn, and ten diagnostics/research tools companies were acquired, five of which together were valued at $22.6bn.
Biodesix is expanding its portfolio of lung cancer diagnostic tests and acquiring the US assets of UK company Oncimmune.
Oncimmune, the UK specialist in autoantibody-based tests for early cancer detection, has bullked up its human and financial resources with the appointment of a chief medical and strategy officer, and the closing of an investment tranche from its Chinese partner.